ReviewJournal of biotechnology2000
Adenoviruses as vectors for delivering vaccines to mucosal surfaces.
Review in Journal of biotechnology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.Acta pharmaceutica Sinica. B · 2022Review
- Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.Drug delivery and translational research · 2017Review
- Article
- Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.Clinical and vaccine immunology : CVI · 2012Article
- Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Nature reviews. Urology · 2012Review
- An adenoviral vector-based mucosal vaccine is effective in protection against botulism.Gene therapy · 2009Article
- Recombinant vectors as influenza vaccines.Current topics in microbiology and immunology · 2009Review
- Polarization of protective immunity induced by replication-incompetent adenovirus expressing glycoproteins of pseudorabies virus.Experimental & molecular medicine · 2008Article
- Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.Vaccine · 2008Review
- Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.Clinical and vaccine immunology : CVI · 2007Article
- Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus.Journal of virology · 2005Article
- Use of adenoviral vectors as veterinary vaccines.Gene therapy · 2005Review
- Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics.Veterinary journal (London, England : 1997) · 2005Review
- In vivo phage display to identify M cell-targeting ligands.Pharmaceutical research · 2004Article
- The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.Transactions of the American Clinical and Climatological Association · 2004Article
- Mucosal immunity: overcoming the barrier for induction of proximal responses.Immunologic research · 2004Review
- Detailed analysis of the CD8+ T-cell response following adenovirus vaccination.Journal of virology · 2003Article
- T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunization of mucosal surfaces has become an attractive route of vaccine delivery because of its ability to induce mucosal immunity. Although various methods of inducing mucosal immunity are being developed, our laboratory has focused on developing adenoviruses as replication-competent and replication-incompetent vectors. The present report will summarize our progress in sequencing the entire bovine adenovirus-3 genome and identifying regions which can be deleted and subsequently used as insertion sites for foreign genes in developing recombinant viral vaccines. Using these recombinant viruses, we demonstrated the 'proof-of-principle' in developing mucosal immunity and, more importantly, inducing protection against bovine herpes virus in a natural host-cattle. Finally, we demonstrated that immunity and protection occurred even in animals that had pre-existing antibodies to the vector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.